medigraphic.com
Sociedad Mexicana de Dermatología y Academia Mexicana de Dermatología.

2008, Número 1

Dermatol Rev Mex 2008; 52 (1)


Diagnóstico y tratamiento del linfoma cutáneo de células T

Juárez NL, Rincón PC, Tovar FR, Moreno CCA

Idioma: Inglés
Referencias bibliográficas: 32
Paginas: 10-19
Archivo PDF: 187.40 Kb.


RESUMEN

Los linfomas cutáneos primarios de células T (LCCT) más frecuentes en la práctica dermatológica son la micosis fungoide y el síndrome de Sézary. Es importante que el clínico conozca el abordaje inicial ante un paciente con diagnóstico de linfoma cutáneo de células T, con la finalidad de realizar una estadificación adecuada e iniciar el tratamiento apropiado. En este escrito se revisan los diferentes estudios de laboratorio y gabinete que deben solicitarse. Se revisan también las diversas opciones terapéuticas, como tratamientos tópicos y sistémicos, sus indicaciones, efectos secundarios y dosis. Actualmente los modificadores de la respuesta biológica ofrecen una alternativa de tratamiento para estos pacientes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Rincón PC, Juárez NL. Linfomas cutáneos: fisiopatología y clasificación (primera parte). Rev Mex Dermatol 2005;49:109-22.

  2. Scarisbrick JJ. Staging and management of cutaneous T-cell lymphoma. Clin Exp Dermatol 2006;31:181-6.

  3. Whittaker SJ, Marsden JR, Spittle M, Russel JR. Joint British Association of Dermatologist and UK Cutaneous Lymphoma Group Guidelines for the Management of primary cutaneous T-cell lymphomas. B J Dermatol 2003; 149:995-1107.

  4. Massone C, Kodama K, Kerl H, Cerroni L. Histopathologic features of early (patch) lesions of mycosis fungoides: a morphologic study on 745 biopsy specimens from 427 patients. Am J Surg Pathol 2005;29(4):550-60.

  5. Fung MA, Murphy MJ, Hoss DM. Practical evaluation and management of cutaneous lymphoma. J Am Acad Dermatol 2002;46(3):325-60.

  6. Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005;53:1053-63.

  7. Willemze Rein, Jaffe ES, Burg G, Cerroni L, Berti E, et al. WHO-EORT classification for cutaneous lymphomas. Blood 2005;105(10):3768-82.

  8. Dogan A, Morice WG. Bone marrow histopathology in peripheral T-cell lymphomas B J Haematol 2004:127(2):140-54.

  9. Tsai EY, Taur A, Espinosa L, Quon A, et al. Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol 2006;142:577-84.

  10. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides: experience in 79 patients. Arch Dermatol 1998;134:949-54.

  11. Ballow M, Nelson R. Immunopharmacology: immunomodulation and immunotherapy. JAMA 1997;278:2008-17.

  12. Zackheim HS, Kasani-Sabet M, Amin S. Topical carmustine (BCNU) for cutaneous T-cell lymphomas: A 15 year experience in 143 patients. J Am Acad Dermatol 1990;22(5):802-9.

  13. Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides. Arch Dermatol 2003;139:65-173.

  14. De Quatrebarbes J, Esteve E, Bagot M, Bernard P, et al. Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: A prospective study. Arch Dermatol 2005;141(9):1117-20.

  15. Saskia A, Borwhuis MD, Marck D, Davis RA, et al. Bexaroteno treatment of late-stage mycosis fungoides and Sézary syndrome: development o extracutaneous lymphoma in 6 patients. J Am Acad Dermatol 2005;52(6):991-6.

  16. Duvic M, Hymes K, Heald P. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19(9);2456-71.

  17. McGinnis KS, Junkins-Hopkins JM, Crawford G, Shapiro M, et al. Low-dose oral bexacarotene in combination whit low-dose interferon alfa in the treatment of cutaneous T-cell lymphomas: Clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol 2004;50(3):375-9.

  18. Assaf C, Bagot M, Dummer R, Duvic M, et al. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 2006;155:261-6.

  19. Jacob A. Open label pilot study of combination therapy with roziglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 2007;56(4):584-7.

  20. Chiam LT, Chan YC. Solitary plaque mycosis fungoides on the penis responding to topical imiquimod therapy. Br J Dermatol 2006;156:560-2.

  21. Suchin KR, Junkins-Hopkins JM, Rook AH. Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol 2002;138:1137-9.

  22. Jones GW, Kacinski BM, Wilson LD, Willemze R, et al. Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization of Research and Treatment of Cancer (EORT) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 2002;47:364-70.

  23. Romo EM, Moreira PM, López PA. Uso de los interferones en dermatología: experiencia con el alfa interferón en la micosis fungoide. Rev Cub Farm 2004; 38(2):

  24. Jumbou O, N’Guyen JM, Tessier MH, Legoux B, Dréno B. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa. Br J Dermatol 1999;3:427-31.

  25. Mori M, Campoimi P, Mavilia L, Rossi R, Cappugi P. Monochromatic eximer light (308 nm) in patch-stage IA mycosis fungoides. J Am Acad Dermatol 2004;50:943-5.

  26. Boztepe G, Sahin S, Aynan M, Erkin G, Killemen F. Narrowband ultraviolet B phototherapy to clear and maintain clearance in patients with mycosis fungoides. J Am Acad Dermatol 2005;53:242-6.

  27. Querfeld C, Rosen ST, Kuzel TM, Kirby KA, et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoraleno plus UV-A monotherapy. Arch Dermatol 2005; 141:305-11

  28. Taub AF. Photodynamic therapy: other uses. Dermatol Clin 2007;25:101-9.

  29. Wollina U, Looks A, Mayer J, Knopf B, et al. Treatment of stang II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy. J Am Acad Dermatol 2001;44:253-60.

  30. Querfeld C, Rosen ST, Guitart J, Rademaker A, et al. Phase II trial of subcutaneous injections of human recombinant interleukin- 2 for the treatment of mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 2007;56:580-3.

  31. Querfeld C, Rosen ST, Guitar J, Kuzel TM. The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. Curr Opin Hematol 2005;12:273-8.

  32. Demierre MF, Taverna J. Mitarzapine and gabapentin for reducing pruritus in cutaneous T-cell. J Am Acad Dermatol 2006;55(3):543-4.




2020     |     www.medigraphic.com